06:42 AM EST, 02/03/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its drug, Imfinzi, was recommended for approval in the European Union as a monotherapy for limited-stage small cell lung cancer in adults.

The company said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use was based on phase 3 trial results, demonstrating that Imfinzi reduced the risk of death by 27%, compared to placebo.